Home  »  Companies   »  Is There a Dimmer Outlook Ahead for Baudax Bio Inc...

Is There a Dimmer Outlook Ahead for Baudax Bio Inc. (BXRX)?

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

Baudax Bio Inc. (NASDAQ:BXRX) went down by -1.20% from its latest closing price compared to the recent 1-year high of $2.12. The company’s stock price has collected -10.22% of loss in the last five trading sessions. Press Release reported on 01/04/22 that Baudax Bio to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

Is It Worth Investing in Baudax Bio Inc. (NASDAQ :BXRX) Right Now?

Opinions of the stock are interesting as 3 analysts out of 3 who provided ratings for Baudax Bio Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


The average price from analysts is $1.83, which is $1.62 above the current price. BXRX currently public float of 83.59M and currently shorts hold a 2.57% ratio of that float. Today, the average trading volume of BXRX was 2.29M shares.

BXRX’s Market Performance

BXRX stocks went down by -10.22% for the week, with a monthly drop of -44.22% and a quarterly performance of -62.56%, while its annual performance rate touched -84.12%. The volatility ratio for the week stands at 13.56% while the volatility levels for the past 30 days are set at 10.19% for Baudax Bio Inc.. The simple moving average for the period of the last 20 days is -27.76% for BXRX stocks with a simple moving average of -69.11% for the last 200 days.

Analysts’ Opinion of BXRX

Many brokerage firms have already submitted their reports for BXRX stocks, with JMP Securities repeating the rating for BXRX by listing it as a “Mkt Outperform.” The predicted price for BXRX in the upcoming period, according to JMP Securities is $13 based on the research report published on May 15th of the previous year 2020.

BXRX Trading at -46.57% from the 50-Day Moving Average

After a stumble in the market that brought BXRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -90.26% of loss for the given period.

Volatility was left at 10.19%, however, over the last 30 days, the volatility rate increased by 13.56%, as shares sank -39.51% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -63.50% lower at present.

During the last 5 trading sessions, BXRX fell by -10.22%, which changed the moving average for the period of 200-days by -84.59% in comparison to the 20-day moving average, which settled at $0.2791. In addition, Baudax Bio Inc. saw -5.79% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at BXRX starting from HENWOOD GERALDINE, who purchase 8,200 shares at the price of $0.59 back on Sep 22. After this action, HENWOOD GERALDINE now owns 364,507 shares of Baudax Bio Inc., valued at $4,798 using the latest closing price.

CHURCHILL WINSTON J, the Director of Baudax Bio Inc., purchase 100,000 shares at $0.63 during a trade that took place back on Aug 31, which means that CHURCHILL WINSTON J is holding 257,185 shares at $62,930 based on the most recent closing price.

Stock Fundamentals for BXRX

Current profitability levels for the company are sitting at:

  • -11319.88 for the present operating margin
  • -769.37 for the gross margin

The net margin for Baudax Bio Inc. stands at -15436.11. Equity return is now at value 644.80, with -95.00 for asset returns.

>> 7 Top Picks for the Post-Pandemic Economy <<

When we switch over and look at the enterprise to sales, we see a ratio of -3.82, with the company’s debt to enterprise value settled at -9.64. The receivables turnover for the company is 19.33 and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.03.

Leave a Comment

Your email address will not be published. Required fields are marked *

Is Teradyne Inc. (TER) a Keeper?

Teradyne Inc. (NASDAQ:TER) went up by 3.99% from its latest closing price compared to the recent 1-year high of $168.91. The company’s stock price has




Download Free eBook For


100% free. stop anytime no spam